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Abstract
Background: Quality of life (QoL) is profoundly impaired in patients with idiopathic pulmonary fibrosis (IPF).
However, data is limited regarding the course of QoL. We therefore analysed longitudinal data from the German
INSIGHTS-IPF registry.
Methods: Clinical status and QoL were assessed at enrollment and subsequently at 6- to 12-months intervals. A
range of different QoL questionnaires including the St. George’s Respiratory Questionnaire (SGRQ) were used.
Results: Data from 424 patients were included; 76.9% male; mean age 68.7 ± 9.1 years, mean FVC% predicted 75.9 ± 19.4,
mean DLCO% predicted 36.1 ± 15.9. QoL worsened significantly during follow-up with higher total SGRQ scores
(increased by 1.47 per year; 95% CI: 1.17 to 1.76; p < 0.001) and higher UCSD-SOBQ scores and lower EQ-5D VAS and
WHO-5 scores. An absolute decline in FVC% predicted of > 10% was associated with a significant deterioration in SGRQ
(increasing by 9.08 units; 95% CI: 2.48 to 15.67; p = 0.007), while patients with stable or improved FVC had no significantly
change in SGRQ. Patients with a > 10% decrease of DLCO % predicted also had a significant increase in SGRQ (+ 7.79 units;
95% CI: 0.85 to 14.73; p = 0.028), while SQRQ was almost stable in patients with stable or improved DLCO. Patients who
died had a significant greater increase in SGRQ total scores (mean 11.8 ± 18.6) at their last follow-up visit prior to death
compared to survivors (mean 4.2 ± 18.9; HR = 1.03; 95% CI: 1.01 to 1.04; p < 0.001). All QoL scores across the follow-up
period were significantly worse in hospitalised patients compared to non-hospitalised patients, with the worst scores
reported in those hospitalised for acute exacerbations.
Conclusions: QoL assessments in the INSIGHTS-IPF registry demonstrate a close relationship between QoL and clinically
meaningful changes in lung function, comorbidities, disease duration and clinical course of IPF, including hospitalisation
and mortality.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a severe disease
characterised by debilitating symptoms such as cough,
fatigue, increasing and immobilising dyspnoea and is as-
sociated with a limited survival [1, 2]. IPF symptoms and
outcomes are also strongly influenced by co-morbidities
[3, 4]. The psychosocial impact of IPF is substantial for
both patients and their caregivers [1, 5]. Recent reports
have shown that in IPF patients health-related quality of
life (QoL) is associated with clinical symptoms, duration
of disease, physical activity, comorbidities, and disease
severity [6–10] and may be prognostic [11].
While current therapies aim to improve the disease
course and to prolong life expectancy, less well under-
stood is how best to improve an individual’s
health-related quality of life and psychosocial needs [12].
To address this, patient-reported outcomes incorporat-
ing determination of health-related quality of life (QoL)
assessments are increasingly used as important outcome
measures, in clinical practice and in clinical trials [6].
However, data on longitudinal determinations of QoL in
IPF patients, especially in the real-life setting are sparse.
Previously, we have reported on baseline characteristics
and QoL status in patients enrolled in a large nationwide
observational IPF registry (INSIGHTS-IPF) [2, 7]. In the
present analyses, we report longitudinal data (with up to
36months follow-up) for a range of QoL measures and
examine changes in QoL outcomes and their relation-
ship to clinical parameters.
Methods
Study population
The INSIGHTS-IPF (“Investigating significant health
trends in idiopathic pulmonary fibrosis”) registry is a na-
tionwide, investigator-initiated cohort study, which has
been continuously enrolling consecutive patients in rou-
tine clinical care across 19 pulmonary specialist centres
in Germany since November 2012. Patients ≥18 years of
age with a study-site diagnosis of IPF after provision of
written informed consent can be enrolled, with no expli-
cit exclusion criteria. The registry’s structure, method-
ology and regulatory aspects, and a detailed description
of the baseline characteristics of the patient cohort have
been reported [2, 13, 14]. Patients with a QoL assess-
ment at baseline and at least one follow-up assessment
were available for this study. The change in QoL was
studied for 3 years after enrolment into the registry (i.e.,
3-year follow-up), because of the currently limited num-
ber of patients (n = 24) with available QoL data for
follow-up beyond this time-point.
Clinical and patient-reported outcome measures
Data were collected at enrolment (baseline) and at sub-
sequent 6- to 12months intervals. At each follow-up
visit, all clinical events including hospitalisation and
acute exacerbations (as judged by the treating physician),
and death were recorded by each site. At these visits, a
range of routine pulmonary function tests were docu-
mented, including forced vital capacity (FVC) % pre-
dicted, diffusing capacity of the lung for carbon
monoxide (DLCO) % predicted, the forced expiratory vol-
ume in 1 s (FEV1), and six-minute walk distance
(6MWD). The Gender, Age, Physiology (GAP) index was
also determined. All patients completed the NYHA
functional status and a range of QoL questionnaires as
previously reported [7]. These include the St. George’s
Respiratory Questionnaire (SGRQ), the University of
California San Diego Shortness of Breath Questionnaire
(USCD-SOBQ), the EuroQol five-dimensional question-
naire, recorded as a visual analogue scale (EQ-VAS), and
the World Health Organization-5 Well-Being Index
(WHO-5). At each visit, where possible the treating
physician made and recorded their judgement of overall
disease course (stable disease, slow progression, rapid
progression) according to Behr et al. (2). Functional
changes were categorized as stable/increased if FVC did
not change or was improved by ≥0%, as a moderate de-
crease between > 0–10% and a significant decrease in
case of > 10%.
All data were collected using an internet-based case
report form (eCRF) with secure electronic data transfer
to the central database. Quality measures included auto-
mated plausibility checks at data entry, statistical checks
on data quality (focussing on missing values and out-
liers) as well as on-site monitoring and source data veri-
fication performed in the majority of centres (over 70%).
Data analysis
Data were summarised by descriptive statistics including
means and standard deviations and absolute and relative
frequencies at baseline and each subsequent follow-up
assessment. Baseline characteristics were compared by
t-test for continuously distributed variables and Chi2 test
for categorical variables between patients who were in-
cluded in the analyses and excluded by missing QoL as-
sessments. Linear mixed models were applied to
investigate the change in QoL in follow-up with the
study centres as cluster variable. Clinical characteristics
such as lung function test at baseline (time invariant)
and follow-up (time varying) were used to analyse pos-
sible associations with the change in QoL across time by
linear mixed models. The association of mortality with
QoL at the last available follow-up and change in QoL
between baseline and last follow-up was analysed by
Cox proportional hazard models. Hospitalisations for
any reason and hospitalisations due to exacerbation in
follow-up were investigated by linear mixed models.
Multivariable regression models for mortality and
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hospitalisations included lung function test, the num-
ber of comorbidities, age and the physicians global
judgement about disease activity as covariates. A
p-value of lower than 0.05 was considered to be sta-
tistically significant.
Data were analysed with STATA 12.1 (StataCorp LP.
Stata Statistical Software: Release 12. College Station,
TX, USA).
Results
Patient characteristics
Of 879 patients, a total of 424 patients provided QoL
data at baseline and at least at one follow-up visit, and
were included in these analyses. Baseline characteristics
of this cohort are presented in Table 1. Baseline charac-
teristics for patients who were not included due to miss-
ing follow-up assessment of QoL -in comparison to the
cohort reported here- are presented in Additional file 1:
Table S4. For this the cohort, the patients mean age was
68.7 ± 9.1 years, 76.9% were male, and mean symptom
duration was 3.7 ± 4.1 years, with 61.3% having disease
for more than 6months at registry enrolment; 60.4% of
participants were former smokers with 38.0% never hav-
ing smoked. Most patients (77.6%) had one or more co-
morbidities. At baseline, the IPF was judged by treating
physicians as stable in 39.2% of patients, slowly progres-
sing in 29.0% and rapidly progressing in 7.3%. Most pa-
tients were in NYHA functional class II/III at
enrolment, with a mean 6MWD of 288 ± 200 m. Mean
values for respiratory parameters were; FVC % predicted
(75.9% ± 19.4), FEV1% (68.3% ± 17.4), and DLCO % pre-
dicted (36.1% ± 15.9); 53.0% were in GAP index stage 2
and 28.2% in stage 3.
At baseline the mean SGRQ total score was 45.9 ±
19.7, with higher scores for the SGRQ activity domain
(59.7 ± 23.6) than symptom or impact domains. Patient
reported breathlessness with a mean USCD-SOBQ score
of 43.9 ± 28.8. Mean EQ-5D VAS scores were 62.6 ± 1
8.5 with mean WHO-5 scores of 14.8 ± 5.7.
Change in QoL over time and associations to clinical
parameters during follow up
The courses for QoL scores from baseline to last
follow-up visit are shown in Fig. 1 (and in online data
supplement; Additional file 2: Table S1). Longitudinal
data showed a significant increase in SGRQ total scores
(beta = 1.47, 95% CI: 1.17 to 1.76; p < 0.001) and
UCSD-SOBQ score (beta = 3.63, 95% CI: 3.07 to 4.18;
p < 0.001) per half-year between baseline and
36-months follow-up (indicating poorer QoL compared
to baseline). EQ-5D VAS scores and WHO-5 scores
also significantly decreased across time indicating a
worsening QoL (Additional file 2: Table S1).
Table 1 Sociodemographic and clinical parameters of the
patient cohort analysed
Patient characteristics n (%) / mean (SD)
n = 424
Female 98 (23.1%)
Age in years 68.7 (9.1)
Age at first symptom onset in years 64.9 (10.3)
Age at diagnosis in years 66.8 (9.7)
Duration since first symptoms in years 3.7 (4.1)
Disease duration in months 2.0 (2.7)
< 3 months 124 (29.5%)
3 to < 6 months 39 (9.3%)
More than 6months 258 (61.3%)
Smoking status
Never 161 (38.0%)
Former stopped 256 (60.4%)
Current 7 (1.7%)
Number of comorbidities
None 95 (22.4%)
1 124 (29.3%)
2 107 (25.2%)
3 63 (14.9%)
4+ 35 (8.3%)
NHYA
I 28 (14.7%)
II 81 (42.6%)
III 76 (40.0%)
IV 5 (2.6%)
Six-minute walk distance (m) 287.7 (199.6)
% FEV1 68.3 (17.4)
% FVC 36.1 (15.9)
% DLCO 75.9 (19.4)
GAP index 4.7 (1.4)
Stage I 72 (18.8%)
Stage II 203 (53.0%)
Stage III 108 (28.2%)
Overall physician’s judgement of clinical course of IPF
Stable disease 166 (39.2%)
Slow progression 123 (29.0%)
Rapid progression 31 (7.3%)
No judgement possible 104 (24.5%)
SGRQ 45.9 (19.7)
SGRQ symptoms 55.9 (21.0)
SGRQ activity 59.7 (23.6)
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Details about the association between the different
QoL measures and clinical characteristics at baseline
and change in clinical parameters in follow-up are re-
ported in Table 2. Female patients reported significant
higher, i.e. poorer SGRQ scores during follow-up (beta =
5.42, 95% CI: 1.13 to 9.71; p = 0.013) compared to males.
A higher NYHA stage, GAP index and a more severe as-
sessment of the clinical course of the patient by the
treating physician at baseline were associated with
higher, i.e. worse SGRQ scores. The more impaired the
lung function was at baseline, the higher were the SQRQ
scores during follow-up. Patients with more than a 10%
decrease of FVC % predicted and/or DLCO % predicted
within 1 year reported significantly worse SQRQ scores
during follow-up compared to stable patients; FVC %
predicted (beta = 9.08; 95% CI: 2.48 to 15.67; p =
0.007); DLCO % predicted (beta = 7.79; 95% CI: 0.85 to
14.73; p = 0.028). Comparable results were observed
for the other QoL measures (Table 2).
SGRQ at last follow-up, and change in SGRQ between
baseline and last follow-up in association to lung func-
tional changes within 1 year are shown in Fig. 2. More
complete data for the SGRQ and those for all other QoL
measures are presented in the online data supplement
(Additional file 2: Table S2). The deterioration in SGRQ
scores until last follow-up was associated with a worsen-
ing of FVC % predicted and DLCO % predicted within 1
year after enrolment. In patients with stable or even im-
proving, i.e. increasing FVC % predicted, SGRQ scores
after 36months follow-up remained relatively unchanged
from baseline (mean − 0.1 units ‡ 21.1) with SGRQ at
36-months of 45.7 units ‡ SD 19.5. In contrast, compared
to these patients, those patients with a decline of > 10% in
FVC % predicted reported a significantly higher increase
in SQRQ scores from baseline (mean 20.6 ‡19.1, beta =
20.71; 95% CI: 13.09 to 28.33; p < 0.001) and significantly
higher SGRQ scores at last follow-up (mean = 64.1 ‡ 19.6,
beta = 18.43; 95% CI: 10.98 to 25.87). There was also a
non-significant trend towards a worse SGRQ for patients
with a moderate lung functional decline compared to
Table 1 Sociodemographic and clinical parameters of the
patient cohort analysed (Continued)
Patient characteristics n (%) / mean (SD)
n = 424
SGRQ impacts 34.8 (20.7)
UCSD-SOBQ 43.9 (28.8)
EQ-5D VAS 62.6 (18.5)
WHO-5 14.8 (5.7)
Values are n (%) or mean (SD)
DLCO diffusing capacity of the lung for carbon monoxide, EQ-5D VAS EuroQol
five-dimensional questionnaire, recorded as a visual analog scale, FEV1 Forced
expiratory volume in 1 s, FVC forced vital capacity, GAP index Gender, Age,
Physiology index, IPF idiopathic pulmonary fibrosis, NYHA New York Heart
Association functional class, SD standard deviation, SGRQ St. George’s
Respiratory Questionnaire, USCD-SOBQ University of California San Diego
Shortness of Breath Questionnaire, WHO-5 World Health Organization-5
Well-Being Index
Fig. 1 Change in QoL over 3 years of follow-up SGRQ (p < 0.001), SGRQ symptoms (p = 0.142), SGRQ activity (p < 0.001), SGRQ impacts (p < 0.001),
EQ-5D VAS (p < 0.001), UCSD Shortness of breath (p < 0.001), WHO-5 (p < 0.001)) over 3 years of follow-up. EQ-5D VAS, EuroQol five-dimensional
questionnaire, recorded as a visual analog scale; QoL, quality of life; SGRQ, St. George’s Respiratory Questionnaire; USCD-SOBQ, University of
California San Diego Shortness of Breath Questionnaire; WHO-5, World Health Organization-5 Well-Being Index
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Table 2 Associations of QoL with clinical parameters at baseline and change in clinical parameters in follow-up
SGRQ total EQ 5D VAS UCSD-SOBQ WHO-5
beta 95% CI p-value beta 95% CI p-value beta 95% CI p-value beta 95% CI p-value
Female sex 5.42 1.13; 9.71 0.013 −3.36 −6.90; 0.18 0.063 13.56 6.41; 20.72 < 0.001 − 1.47 −2.60; − 0.33 0.011
Age 0.00 −0.19; 0.20 0.963 −0.18 − 0.34; − 0.02 0.029 0.35 0.04; 0.66 0.026 −0.05 − 0.10; 0.00 0.074
Age at first symptom
onset in years
−0.10 − 0.28; 0.08 0.285 − 0.08 − 0.22; 0.07 0.323 0.17 − 0.11; 0.46 0.238 − 0.03 − 0.07; 0.02 0.299
Age at diagnosis in
years
−0.09 − 0.28; 0.09 0.320 − 0.08 − 0.23; 0.07 0.290 0.18 − 0.11; 0.48 0.227 − 0.02 − 0.07; 0.03 0.400
Duration since first
symptoms in years
0.73 0.28; 1.18 0.002 −0.51 −0.89; − 0.13 0.008 0.71 − 0.04; 1.46 0.062 − 0.09 − 0.21; 0.03 0.139
Disease duration
in months
1.36 0.70; 2.02 < 0.001 −1.10 − 1.65; −0.55 < 0.001 1.70 0.64; 2.77 0.002 −0.25 −0.43; − 0.08 0.005
< 3 months 1.00 1.00 1.00 1.00
3 to < 6 months −2.63 −9.30; 4.04 0.440 1.30 −4.28; 6.89 0.647 −4.48 −16.06; 7.11 0.449 0.54 −1.27; 2.34 0.560
More than 6 months 6.54 2.53; 10.55 0.001 −5.10 −8.43; − 1.76 0.003 8.43 1.74; 15.12 0.014 −0.68 −1.76; 0.40 0.215
Number of comorbidities
None 1.00 1.00 1.00 1.00
1 3.55 −1.37; 8.47 0.157 −5.19 −9.23; − 1.16 0.012 9.93 2.05; 17.80 0.013 −0.86 −2.16; 0.44 0.195
2 4.49 −0.63; 9.61 0.086 −6.46 −10.66; −2.26 0.003 10.11 1.88; 18.34 0.016 −1.02 −2.37; 0.33 0.140
3 5.87 −0.04; 11.78 0.051 −7.75 − 12.62; −2.88 0.002 15.37 5.74; 24.99 0.002 −1.98 −3.55; −0.41 0.013
4+ 17.18 10.14; 24.23 < 0.001 −14.99 −20.88; −9.11 < 0.001 33.06 20.77; 45.35 < 0.001 −4.35 −6.24; −2.46 < 0.001
NHYA
I 1.00 1.00 1.00 1.00
II 16.07 9.16; 22.98 < 0.001 −12.61 −19.06; −6.15 < 0.001 22.28 10.78; 33.77 < 0.001 −1.86 −3.92; 0.21 0.078
III 26.95 19.97; 33.93 < 0.001 −18.00 −24.49; − 11.50 < 0.001 38.29 26.65; 49.92 < 0.001 −3.82 −5.90; − 1.75 < 0.001
IV 33.28 16.44; 50.13 < 0.001 −27.35 −41.90; − 12.81 < 0.001 51.63 24.63; 78.64 < 0.001 −8.69 −13.43; − 3.95 < 0.001
6MWD (m) − 0.01 − 0.01; 0.00 0.217 0.00 0.00; 0.01 0.313 −0.01 − 0.03; 0.00 0.109 0.00 0.00; 0.00 0.423
FEV1% predicted −0.55 −0.62; − 0.49 < 0.001 0.43 0.37; 0.49 < 0.001 − 0.80 − 0.91; − 0.70 < 0.001 0.09 0.07; 0.11 < 0.001
FVC % predicted − 0.60 − 0.66; − 0.53 < 0.001 0.46 0.39; 0.53 < 0.001 −0.89 −1.00; − 0.78 < 0.001 0.11 0.09; 0.13 < 0.001
DLCO % predicted −0.26 − 0.31; − 0.20 < 0.001 0.26 0.20; 0.33 < 0.001 − 0.35 − 0.44; − 0.25 < 0.001 0.04 0.02; 0.06 < 0.001
Change in FVC % predicted between baseline and 1-year follow-up
Stable/increase 1.00 1.00 1.00 1.00
Decrease by 0
to 10%
3.71 −0.55; 7.97 0.087 −2.90 −6.58; 0.77 0.122 4.08 −3.13; 11.29 0.267 −0.51 −1.67; 0.65 0.393
Decrease by
> 10%
9.08 2.48; 15.67 0.007 −8.07 −13.81; −2.33 0.006 11.24 0.32; 22.16 0.044 −1.30 −3.09; 0.50 0.156
Change in DLCO % predicted between baseline and 1-year follow-up
Stable/increase 1.00 1.00 1.00 1.00
Decrease by 0
to 10%
5.46 0.85; 10.08 0.020 −0.41 −4.43; 3.60 0.841 10.46 2.85; 18.07 0.007 −0.37 −1.62; 0.88 0.561
Decrease by
> 10%
7.79 0.85; 14.73 0.028 −3.93 −9.96; 2.10 0.201 10.74 −0.73; 22.21 0.067 −0.40 −2.28; 1.47 0.673
Change in FVC % predicted between baseline and last follow-up
Stable/increase 1.00 1.00 1.00 1.00
Decrease by 0
to 10%
3.44 −1.04; 7.92 0.133 −3.30 −7.08; 0.48 0.087 3.18 −4.45; 10.81 0.414 −0.22 −1.44; 0.99 0.719
Decrease by
> 10%
7.47 2.11; 12.83 0.006 −6.50 −11.02; − 1.99 0.005 8.80 −0.15; 17.75 0.054 −0.87 −2.32; 0.59 0.242
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stable patients. A similar pattern was seen when
comparing patients with a decline of > 10% in DLCO %
predicted with those with stable/improving DLCO % pre-
dicted (Fig. 2). Similar associations were also seen for
other QoL scores (SQRQ symptom, activity and impact
domains, and UCSD-SOBQ, EQ-5D, WHO-5) (Online
data supplement; Additional file 2: Table S2).
Association of QoL and mortality
Over the study period there were 113 deaths (26.7% of all
included patients). Univariate analysis found that change
from baseline to last visit in any QoL outcome scores (i.e.,
SGRQ total score, UCSD-SOBQ, EQ-5D VAS, and
WHO-5) were each predictive of mortality (Fig. 3). Pa-
tients who died during follow up in this cohort had a sig-
nificant greater increase in SGRQ total scores from
baseline to their last follow-up visit prior to death (mean
11.8 ± 18.6) compared to surviving patients (mean 4.2 ±
18.9; HR = 1.03; 95% CI: 1.02 to 1.05; p < 0.001). Changes
from baseline in UCSD-SOBQ scores in patients who died
and survivors were 7.0 ± 29.1 and 20.4 ± 1.5 respectively;
HR = 1.03; 95% CI: 1.01 to 1.04; p < 0.001. In patients who
died, the SGRQ and UCSD-SOBQ scores reported at last
follow-up visit were all significantly higher (and EQ-5D
VAS, and WHO-5 scores significantly lower) compared to
surviving patients (Fig. 3).
After adjusting for change in FVC% predicted, age,
number of comorbid diseases, hospitalisation during
follow-up and the physician’s global assessment about
the disease course, multivariate analysis found that a
lower QoL at last available follow-up was significantly
associated with mortality (Table 3). When evaluating
mortality and SGRQ scores at last available follow-up,
higher age (HR = 1.06; 95% CI: 1.03 to 1.09; p < 0.001)
and a > 10% decline in FVC % predicted (HR = 2.34, 95%
CI: 1.18 to 4.62; p = 0.015) were each associated with
mortality. Furthermore, the higher the number of co-
morbid diseases the higher the risk for mortality (none
versus one: HR = 2.40, 95% CI: 1.15 to 5.01; p = 0.02;
none versus two: HR = 2.10, 95% CI: 1.02 to 4.32; p =
0.043; none versus three: HR = 2.78, 95% CI: 1.26 to
6.09; p = 0.011). Comparable results were found for the
other QoL measures at last follow-up. In contrast, no
significant associations between change from baseline to
last available follow-up in QoL scores and mortality were
observed in multivariate analysis (Table 3).
Association of QoL and hospitalisation and exacerbations
Over the study period 227 patients were hospitalised
for any cause and 31 hospitalised for exacerbations.
Univariate and multivariate analysis found that the
mean SGRQ and UCSD-SOBQ scores across the
follow-up period were all significantly higher (and for
univariate analyses EQ-5D VAS, and WHO-5 score sig-
nificantly lower) in hospitalised patients compared to
non-hospitalised patients, with the highest mean SGRQ
and UCSD-SOBQ scores throughout follow-up (and
lowest EQ-5D VAS and WHO-5 scores) reported in
Table 2 Associations of QoL with clinical parameters at baseline and change in clinical parameters in follow-up (Continued)
SGRQ total EQ 5D VAS UCSD-SOBQ WHO-5
beta 95% CI p-value beta 95% CI p-value beta 95% CI p-value beta 95% CI p-value
Change in DLCO % predicted between baseline and last follow-up
Stable/increase 1.00 1.00 1.00 1.00
Decrease by 0
to 10%
4.41 −0.52; 9.35 0.080 −1.42 −5.59; 2.75 0.505 11.09 2.94; 19.23 0.008 −0.44 −1.77; 0.89 0.518
Decrease by
> 10%
5.10 −0.51; 10.72 0.075 −2.47 −7.18; 2.25 0.305 8.24 −0.88; 17.36 0.077 −0.30 −1.80; 1.21 0.701
GAP index 3.29 1.95; 4.64 < 0.001 −3.41 −4.50; −2.33 < 0.001 6.47 4.36; 8.58 < 0.001 −0.50 − 0.86; − 0.14 0.007
Stage I 1.00 1.00 1.00 1.00
Stage II 5.69 0.74; 10.63 0.024 −7.04 −11.00; −3.08 < 0.001 16.51 8.69; 24.34 < 0.001 −0.92 −2.25; 0.41 0.177
Stage III 12.93 7.42; 18.45 < 0.001 −13.51 − 17.96; −9.07 < 0.001 25.78 17.08; 34.47 < 0.001 − 1.79 −3.27; −0.30 0.019
Overall physician’s judgement of clinical course of IPF
Stable disease 1.00 1.00 1.00 1.00
Slow progression 7.79 3.51; 12.06 < 0.001 −3.52 −7.14; 0.10 0.056 11.13 4.04; 18.21 0.002 −1.08 −2.23; 0.08 0.068
Rapid progression 13.16 6.22; 20.11 < 0.001 −9.52 −15.39; −3.65 0.001 19.89 8.32; 31.47 0.001 −2.72 −4.61; −0.83 0.005
No judgement
possible
−0.39 −4.93; 4.15 0.865 1.33 −2.43; 5.09 0.487 1.72 −5.72; 9.15 0.651 −0.01 −1.23; 1.20 0.986
6MWD six-minute walk distance; beta, regression coefficient, CI confidence interval, DLCO diffusing capacity of the lung for carbon monoxide, EQ-5D VAS
EuroQol five-dimensional questionnaire, recorded as a visual analog scale, FEV1 Forced expiratory volume in 1 s, FVC forced vital capacity, GAP index
Gender, Age, Physiology index, IPF idiopathic pulmonary fibrosis, NYHA New York Heart Association functional class, QoL quality of life, SD standard
deviation, SGRQ St. George’s Respiratory Questionnaire, USCD-SOBQ University of California San Diego Shortness of Breath Questionnaire, WHO-5 World
Health Organization-5 Well-Being Index
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those hospitalised for IPF (Table 4, Fig. 4). Further-
more, across the follow-up period an overall trend was
observed, in which successively greater increases in
mean SGRQ and UCSD-SOBQ scores and successively
greater reductions in EQ-5D VAS and WHO-5 scores
were reported by patients hospitalised on 1, 2, 3 and ≥ 4
separate occasions (Online data supplement;
Additional file 3: Figure S1).
Hospitalisation had an adverse impact upon subsequent
QoL. Following hospitalisation, significantly higher mean
SGRQ scores (total scores and activity and impacts do-
main scores) and higher mean UCSD-SOBQ scores were
reported at the subsequent follow-up visit compared to
those reported at the visit prior to hospitalisation (and sig-
nificantly lower mean EQ-5D VAS and WHO-5 scores)
(Online data supplement; Additional file 2: Table S3).
Discussion
According to the present data, collected from a represen-
tative setting of centres with expertise in the management
of patients with IPF, a close relationship between QoL and
clinical outcomes were found; including clinically mean-
ingful changes in lung function, comorbidities, disease
duration and clinical course of IPF (including hospitalisa-
tion, acute exacerbations and mortality). For these ana-
lyses, we used a range of QoL assessments which,
although not originally designed for IPF, have data to sup-
port their validity in this patient population, as shown in
our previous report and by others [6, 7, 9, 15–18]. The op-
timal tool for QoL assessment in IPF patients remains to
be determined, with an adaptation of the SGRQ specific-
ally for use in IPF not yet fully validated or in widespread
use [19], while other more focused IPF QoL-measures are
also in use or being developed for use (e.g. the Kings’ Brief
Interstitial Lung Disease health status [K-BILD] and the ‘A
Tool to Assess Quality of Life in Idiopathic Pulmonary Fi-
brosis [ATAQ-IPFcA] questionnaires) [9, 20, 21]. It is
likely that, while subtle differences may exist, most current
tools assess QoL with similar sensitivity and with high or
very high correlation between most questionnaires [7, 9].
Fig. 2 QoL at last follow-up visit and Change in QoL from baseline to last follow-up visit by change in lung function. * p-value < 0.05 in
comparison to category ‘stable/ increase’ DLCO % predicted: diffusing capacity of the lung for carbon monoxide % predicted; FVC % predicted,
forced vital capacity % predicted; QoL, quality of life; SGRQ, St. George’s Respiratory Questionnaire
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To our knowledge, the only previous report on longi-
tudinal assessments of QoL in IPF patients in clinical
practice comes from the Australian IPF registry in a
somewhat smaller dataset [6]. In that study, a strong re-
lationship between decline in FVC % predicted and de-
cline in QoL was shown, with QoL impairment mainly
due to dyspnoea (measured using the SGRQ and
UCSD-SOBQ scores) although cough and depression
(assessed by a VAS scale and the Hospital Anxiety and
Depression Scale (HADS)) also contributed [6]. While in
that study, no association between baseline QoL mea-
sures and mortality was found, a more recent report
from the Australian registry indicates that in those pa-
tients with mild physiological impairment (FVC ≥ 80%),
baseline SGRQ and UCSD-SOBQ scores are predictive
of mortality, with HRs of 1.11 (95% CI: 1.06 to 1.15) and
1.23 (95% CI: 1.13 to 1.33) respectively (p < 0.001 for
both) [22]. In contrast to the Australian Registry, we
found a significant relationship between lower QoL at
last available follow-up but no significant association (on
multivariable analysis) between mortality and change in
QoL for the total IPF population. Number of comorbidi-
ties as well as hospitalisations were driving this QoL de-
cline. Notably, significant changes in both FVC and
DLco % predicted values closely reflected changes in
QoL indicating that stabilising lung function may also
halt decline of QoL in IPF.
The overall pattern we observed across the cohort was
a longitudinal decline in QoL. How then can we seek to
improve upon or at least maintain patient QoL in clin-
ical practice? At present, only sparse data on the
long-term effects of available therapies on QoL out-
comes exist. While disease stabilisation by antifibrotic
therapies may offer some potential in maintaining QoL
(or retarding decline), available data to support this goal
remain limited. In the pivotal phase 3 trials evaluating
nintedanib and pirfenidone (each versus placebo), no
significant differences in changes in SGRQ scores (from
baseline to 52 weeks) were seen between the treatment
and placebo arms [23, 24] a finding which could be due
Fig. 3 Association of QoL at last follow-up and change in QoL between baseline and last follow-up with mortality. Light grey and dark grey bares
indicate patients who are censored and died during the observation period, respectively. Hazard ratios adjusted for QoL at baseline. EQ-5D VAS,
EuroQol five-dimensional questionnaire, recorded as a visual analog scale; HR, Hazard ratio; QoL, quality of life; SGRQ, St. George’s Respiratory
Questionnaire; USCD-SOBQ, University of California San Diego Shortness of Breath Questionnaire; WHO-5, World Health Organization-5 Well-Being Index
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Table 3 Multivariable association of A) QoL at last available follow-up and B) change in QoL between Baseline and last available
follow-up and clinical characteristics with mortality
SGRQ total EQ-5D VAS UCSD-SOBQ WHO-5
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
A) Multivariable model including QoL at last available follow-up
QoL at last available follow-up a 1.12 1.06; 1.18 < 0.001 0.91 0.87; 0.96 0.001 1.14 1.08; 1.20 < 0.001 0.83 0.69; 0.99 0.048
Age a 1.32 1.14; 1.54 < 0.001 1.30 1.12; 1.51 0.001 1.27 1.09; 1.48 0.002 1.25 1.07; 1.46 0.006
Number of comorbidities
0 1.00 1.00 1.00 1.00
1 2.40 1.15; 5.01 0.02 1.93 0.98; 3.77 0.057 2.51 0.92; 6.81 0.071 2.03 0.93; 4.41 0.075
2 2.10 1.02; 4.32 0.043 1.62 0.83; 3.19 0.161 2.40 0.90; 6.40 0.079 2.24 1.05; 4.80 0.038
3 2.78 1.26; 6.09 0.011 2.15 1.02; 4.53 0.043 3.16 0.99; 10.05 0.052 2.31 0.97; 5.46 0.057
4+ 1.95 0.69; 5.49 0.205 1.98 0.77; 5.07 0.155 1.30 0.29; 5.86 0.734 2.80 1.00; 7.86 0.051
Change in FVC % predicted
Stable/increase 1.00 1.00 1.00 1.00
Decrease by 0 to 10% 1.63 0.98; 2.71 0.058 1.60 0.97; 2.64 0.066 1.41 0.75; 2.64 0.286 1.75 1.01; 3.03 0.047
Decrease by > 10% 2.34 1.18; 4.62 0.015 2.29 1.16; 4.51 0.017 2.14 0.87; 5.26 0.096 2.70 1.32; 5.53 0.007
Hospitalisation 1.26 0.80; 1.97 0.322 1.54 0.98; 2.40 0.06 1.00 0.57; 1.74 0.994 1.29 0.81; 2.06 0.286
Overall physician’s judgement of clinical course of IPF
Stable disease 1.00 1.00 1.00 1.00
Slow progression 1.48 0.92; 2.38 0.106 1.70 1.08; 2.69 0.022 1.30 0.71; 2.37 0.399 1.91 1.16; 3.17 0.012
Rapid progression 0.97 0.46; 2.04 0.933 1.18 0.55; 2.53 0.674 1.06 0.46; 2.42 0.896 1.25 0.53; 2.95 0.617
No judgement possible 0.89 0.46; 1.74 0.743 0.98 0.52; 1.84 0.95 1.26 0.54; 2.93 0.588 0.94 0.47; 1.91 0.871
B) Multivariable model including change in QoL between baseline and last available follow-up
Change in QoL between baseline and
last available follow-up a
1.05 0.98; 1.13 0.148 0.97 0.91; 1.04 0.364 1.07 0.98; 1.16 0.127 0.85 0.68; 1.07 0.165
Age a 1.30 1.11; 1.52 0.001 1.31 1.12; 1.53 0.001 1.26 1.02; 1.56 0.031 1.26 1.07; 1.48 0.006
Number of comorbidities
0 1.00 1.00 1.00 1.00
1 1.98 0.97; 4.04 0.061 1.83 0.92; 3.63 0.084 2.03 0.71; 5.84 0.187 1.93 0.89; 4.20 0.096
2 1.85 0.90; 3.79 0.092 1.70 0.85; 3.40 0.135 2.01 0.65; 6.21 0.226 2.14 0.99; 4.63 0.054
3 2.40 1.10; 5.24 0.028 2.25 1.06; 4.76 0.035 3.68 1.17; 11.55 0.026 2.18 0.91; 5.23 0.082
4+ 2.04 0.75; 5.57 0.165 2.27 0.87; 5.92 0.093 1.54 0.26; 9.06 0.634 2.99 1.09; 8.22 0.034
Change in FVC % predicted
Stable/increase 1.00 1.00 1.00 1.00
Decrease by 0 to 10% 1.69 1.02; 2.82 0.044 1.65 0.99; 2.76 0.055 1.11 0.57; 2.14 0.762 1.67 0.95; 2.91 0.073
Decrease by > 10% 2.16 1.08; 4.31 0.029 2.26 1.14; 4.50 0.02 1.72 0.71; 4.14 0.227 2.43 1.18; 5.00 0.015
Hospitalisation 1.35 0.85; 2.13 0.202 1.54 0.98; 2.42 0.059 1.30 0.68; 2.45 0.427 1.30 0.81; 2.08 0.285
Overall physician’s judgement of clinical course of IPF
Stable disease 1.00 1.00 1.00 1.00
Slow progression 1.69 1.05; 2.73 0.03 1.83 1.14; 2.94 0.012 1.38 0.67; 2.85 0.381 1.89 1.15; 3.12 0.013
Rapid progression 1.42 0.69; 2.91 0.341 1.63 0.76; 3.46 0.207 1.27 0.47; 3.41 0.636 1.38 0.61; 3.12 0.439
No judgement possible 0.97 0.49; 1.92 0.922 0.96 0.50; 1.83 0.902 1.24 0.52; 2.95 0.622 0.83 0.39; 1.77 0.635
CI confidence interval, EQ-5D VAS EuroQol five-dimensional questionnaire, recorded as a visual analog scale, HR hazard ratio, FVC forced vital capacity,
IPF idiopathic pulmonary fibrosis, QoL quality of life, SD standard deviation, SGRQ St. George’s Respiratory Questionnaire, USCD-SOBQ University of California San
Diego Shortness of Breath Questionnaire, WHO-5 World Health Organization-5 Well-Being Index
a HR for increase by 5 points on the QoL scale or by 5 years of age
Kreuter et al. Respiratory Research           (2019) 20:59 Page 9 of 13
to side effects or to short observation times. Further-
more, this has also to be interpreted in light of the here
reported differences in associations of QoL to lung func-
tional decline which was statistically significant
comparing stable to significantly progressing patients,
i.e. with a decrease of FVC > 10%. However, the differ-
ence to moderately progressive patients, i.e. a decline be-
tween 0 and 10% was only by trend. In the INPULSIS
Table 4 Multivariable association of QoL and clinical characteristics with any hospitalizations and hospitalizations due to
exacerbations in follow-up
SGRQ EQ-5D VAS UCSD-SOBQ WHO-5
beta 95% CI p-value beta 95% CI p-value beta 95% CI p-value beta 95% CI p-value
Any hospitalisation 3.95 0.35; 7.56 0.032 − 0.53 −3.70; 2.64 0.743 8.41 2.46; 14.37 0.006 −0.56 − 1.60; 0.48 0.292
Age −0.04 − 0.26; 0.17 0.702 − 0.21 − 0.39; − 0.02 0.026 0.26 − 0.08; 0.61 0.129 − 0.05 − 0.11; 0.02 0.141
Number of comorbidities
0 0.00 0.00 0.00 0.00
1 −1.61 −7.37; 4.15 0.584 −0.40 −5.40; 4.60 0.875 0.31 −8.64; 9.26 0.946 0.29 −1.25; 1.83 0.714
2 1.82 −3.91; 7.56 0.533 −3.01 −8.19; 2.17 0.255 5.47 −3.72; 14.66 0.243 0.20 −1.36; 1.76 0.801
3 3.36 −2.91; 9.62 0.293 −4.07 −9.51; 1.38 0.143 7.11 −2.70; 16.93 0.155 −0.96 −2.63; 0.71 0.259
4+ 11.42 4.99; 17.85 0.001 −10.18 − 16.28; −4.07 0.001 22.96 11.27; 34.65 < 0.001 −2.64 −5.02; −0.27 0.029
Change in FVC % predicted
Stable/increase 0.00 0.00 0.00 0.00
Decrease by 0 to 10% 3.70 −0.10; 7.51 0.057 −2.93 −6.17; 0.32 0.077 4.60 −1.67; 10.87 0.151 −0.51 −1.62; 0.61 0.375
Decrease by > 10% 8.08 2.23; 13.93 0.007 −6.11 −11.14; − 1.08 0.017 8.91 −0.23; 18.05 0.056 −0.97 −2.59; 0.66 0.242
Overall physician’s judgement of clinical course of IPF
Stable disease 0.00 0.00 0.00 0.00
Slow progression 7.15 4.88; 9.42 < 0.001 −7.24 − 10.05; −4.44 < 0.001 10.65 5.96; 15.35 < 0.001 −1.62 −2.34; − 0.89 < 0.001
Rapid progression 22.68 16.83; 28.52 < 0.001 − 26.37 −32.73; − 20.01 < 0.001 33.57 24.66; 42.48 < 0.001 −6.35 −8.31; −4.40 < 0.001
No judgement
possible
3.02 0.33; 5.70 0.027 −2.15 −5.16; 0.87 0.163 1.70 −2.96; 6.35 0.475 −1.25 −2.11; −0.40 0.004
Hospitalisation by
exacerbation
5.35 0.64; 10.07 0.026 −1.56 −5.78; 2.65 0.468 10.89 2.72; 19.05 0.009 −0.78 −2.32; 0.76 0.320
Age 0.04 −0.24; 0.31 0.791 −0.37 − 0.59; − 0.15 0.001 0.40 − 0.02; 0.82 0.062 − 0.04 −0.12; 0.04 0.383
Number of comorbidities
0 0.00 0.00 0.00 0.00
1 −0.33 −6.99; 6.32 0.922 −1.35 −7.22; 4.51 0.651 1.41 −8.79; 11.61 0.786 0.23 −1.58; 2.04 0.804
2 2.93 −3.86; 9.72 0.397 −2.43 −8.49; 3.64 0.433 6.77 −4.36; 17.89 0.233 −0.09 −2.05; 1.88 0.930
3 3.52 −3.89; 10.93 0.352 −1.79 −8.17; 4.60 0.583 7.09 −5.08; 19.27 0.253 −0.94 −3.15; 1.26 0.403
4+ 13.15 5.95; 20.36 < 0.001 −8.90 −15.99; − 1.82 0.014 21.07 8.29; 33.84 0.001 −2.60 −5.56; 0.36 0.085
Change in FVC % predicted
Stable/increase 0.00 0.00 0.00 0.00
Decrease by 0 to 10% 4.08 −0.73; 8.88 0.096 −4.12 −8.39; 0.15 0.059 6.63 −1.24; 14.50 0.099 −0.75 −2.17; 0.67 0.300
Decrease by > 10% 7.49 0.66; 14.32 0.032 −4.05 −10.00; 1.90 0.182 9.98 −0.91; 20.86 0.072 −1.04 −2.79; 0.72 0.247
Overall physician’s judgement of clinical course of IPF
Stable disease 0.00 0.00 0.00 0.00
Slow progression 6.65 3.84; 9.46 < 0.001 −8.90 −12.49; −5.31 < 0.001 9.98 3.38; 16.58 0.003 −1.63 −2.55; −0.70 0.001
Rapid progression 24.23 17.19; 31.26 < 0.001 −27.75 −36.15; −19.34 < 0.001 33.78 22.82; 44.75 < 0.001 −6.67 −9.06; −4.29 < 0.001
No judgement
possible
2.36 −0.77; 5.49 0.139 −1.16 −4.97; 2.66 0.552 −0.76 −6.46; 4.94 0.794 −0.98 −2.00; 0.03 0.058
beta regression coefficient, CI confidence interval, EQ-5D VAS EuroQol five-dimensional questionnaire, recorded as a visual analog scale, FVC forced vital capacity,
IPF idiopathic pulmonary fibrosis, QoL quality of life, SD standard deviation, SGRQ St. George’s Respiratory Questionnaire, USCD-SOBQ University of California San
Diego Shortness of Breath Questionnaire, WHO-5 World Health Organization-5 Well-Being Index
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trials for example adjusted absolute mean change from
baseline in FVC% was also within this range with − 2.8
for nintedanib and − 6.0 for placebo. Still, a subsequent
pooled analysis of the TOMORROW and INPULSIS tri-
als comparing nintedanib vs. placebo has shown that the
reduction in annual FVC % predicted decline seen in the
nintedanib arms was accompanied by lower increases in
SGRQ compared to placebo (with a mean difference in
adjusted mean change from baseline of − 2.05 [95% CI:
–3.59 to − 0.50]; p < 0.0095) [25]. In the step-IPF study,
sildenafil was reported to positively impact upon QoL in
IPF patients with severe impairment of gas exchange (i.e.
DLco ≤35%) [26]. In a recent randomised controlled trial
using nintedanib and sildenafil in combination (INSTAGE
study) a positive, while non-significant trend on QoL was
observed, but conclusive data is still lacking [27]. On bal-
ance, it is likely that optimising pharmacotherapy in
IPF patients (and reducing decline in lung function)
may also assist in improving QoL in IPF patients. As
groups in cohort studies like ours, e.g. with and
without antifibrotic therapies, inevitably differ in their
clinical characteristics comparisons of therapy effects
on QoL in registries may be subject to bias by indica-
tion. We therefore refrained from performing com-
parative analyses with regards to therapy, which
however should be assessed in future research.
Non-pharmacotherapy treatments are also important.
As physical activity is a strong predictor of IPF disease
course, methods to increase physical activity e.g., pulmon-
ary rehabilitation are important in prolonging a more
positive life-span, in particular as data suggests that pul-
monary rehabilitation may increase QoL [28–30]. Allied
to this, greater attention to assessment and treatment of
comorbid conditions may improve or at least alleviate lon-
gitudinal decline in QoL, although as of yet this remains
unproven [4]. For several patients, early palliative care
may be an appropriate approach [5, 12].
Our study has a number of limitations (above that of
using non-IPF specific QoL measures as discussed above).
Typically for data collection under clinical practice
Fig. 4 Mean QoL scores for patients who were hospitalized (dark grey bares) during follow-up compared to patients who were not hospitalized
(light grey bares). EQ-5D VAS, EuroQol five-dimensional questionnaire, recorded as a visual analog scale; QoL, quality of life; SGRQ, St. George’s
Respiratory Questionnaire; USCD-SOBQ, University of California San Diego Shortness of Breath Questionnaire; WHO-5, World Health Organization-5
Well-Being Index
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conditions, sites showed considerable variance in terms of
number of documented visits and visit time-points, and in
terms of completeness of data (each depending on their
routine clinical schedule) including QoL reports. Further-
more, a potential bias cannot be excluded, such as underre-
porting or underdiagnosing of subacute deterioration and
any influence of social factors (e.g., family situation) and
other aspects external to the disease process. A high num-
ber of patients enrolled were excluded from the present
analyses due to incomplete data of longitudinal QoL assess-
ment. As some differences had been noted between the
group of in- and excluded patients, e.g. a more severe dis-
ease and a higher mean number of comorbidities, a bias of
our results toward patients with a more severe disease
course cannot be excluded. In addition, not every patient
completed each of the QoL questionnaires at least yearly as
stipulated. However, the relatively large numbers of in-
cluded patients and completed QoL measures in connec-
tion with a long follow-up period do provide a substantially
large sample and exposure time from which we found sig-
nificant differences in a number of outcomes, and associ-
ation of QoL changes with clinical status. A final
limitation is that we have not included potential ef-
fects of treatment (including use of anti-fibrotic
agents) in the present analyses and cannot report on
benefits of such treatment.
Conclusions
In conclusion, we found strong associations of changes of
QoL to important outcomes in IPF; principally decline in
lung function, hospitalisation for acute exacerbations and
mortality. Pharmacological and non-pharmacological
therapies used to reduce these clinically important
events should also aim to maintain or even improve
QoL as assessed by these equally important patient-re-
ported outcomes.
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